跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
楊 宗霖
助理教授
,
心臟血管內科
成員
,
臺北醫學大學臺北心臟醫學研究中心
主治醫師
,
臺北醫學大學附設醫院
https://orcid.org/0000-0003-2073-3407
電子郵件
tsunglin.yang
tmu.edu
tw
,
151017
h.tmu.edu
tw
h-index
87
引文
5
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
2012
2025
每年研究成果
概覽
指紋
網路
研究成果
(22)
類似的個人檔案
(12)
指紋
查看啟用 Tsung-Lin Yang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Cardiovascular System
100%
Cohort Analysis
63%
Influenza Vaccination
33%
Breast Cancer
30%
Colorectal Cancer
30%
Hepatocellular Carcinoma
30%
Chronic Kidney Disease
30%
Atrial Fibrillation
30%
Artery Calcification
30%
Side Effect
30%
Pulse Wave Velocity
30%
Chinese Herbal Medicine
30%
COVID-19
30%
Hypotension
30%
Tamoxifen
30%
Acute Coronary Syndrome
30%
Influenza Vaccine
30%
Myocardial Bridge
30%
Cancer Risk
30%
Liver Cancer
30%
Hazard Ratio
27%
Adverse Event
18%
Pulse Rate
16%
Coronary Artery Disease
16%
Cerebral Hemorrhage
15%
Decoction
15%
Myocardial Infarction
14%
Cardiovascular Disease
14%
Brain Ischemia
14%
Neoplasm
12%
Acute Heart Infarction
11%
Survival Time
10%
Drug Therapy
10%
All Cause Mortality
8%
Recommended Drug Dose
7%
P Wave
7%
Intoxication
7%
Sodium Chloride
7%
Anodyne
7%
Infusion
7%
Attitude
7%
Sinus Bradycardia
7%
Cooperation
7%
Traditional Chinese Medicine
7%
Inotropic Agent
7%
Anti-Inflammatory Drug
7%
Sinus Rhythm
7%
Occupation (Patient Social Context)
7%
Cardiotoxicity
7%
Cardiovascular System
7%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
71%
Chronic Kidney Failure
60%
Influenza Vaccine
60%
Acute Heart Infarction
41%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
37%
Comorbidity
32%
Vaccination Policy
31%
End Stage Renal Disease
30%
Aconitum
30%
Colorectal Cancer
30%
Tamoxifen
30%
Breast Cancer
30%
Bilirubin
30%
Liver Cell Carcinoma
30%
Hypotension
30%
Atrial Fibrillation
30%
Heart Failure
30%
Liver Cancer
30%
Myocardial Bridging
30%
Heart Infarction
18%
All Cause Mortality
15%
Brain Hemorrhage
15%
Statin (Protein)
14%
Mortality Rate
14%
Hemodialysis
12%
Brain Ischemia
11%
Survival Time
10%
Dyslipidemia
9%
Neoplasm
9%
Disease Course
8%
Adverse Event
8%
ST Segment Elevation Myocardial Infarction
7%
Beta Adrenergic Receptor Blocking Agent
7%
Dipeptidyl Carboxypeptidase Inhibitor
7%
Angiotensin Receptor Antagonist
7%
Non ST Segment Elevation Myocardial Infarction
7%
Acetylsalicylic Acid
6%
Antihypertensive Agent
6%
Prevalence
6%
Replacement Therapy
6%
Metformin
6%
Liver Disease
6%
Cerebrovascular Disease
6%
Thromboembolism
5%